In last trading session, Evelo Biosciences, Inc. (NASDAQ:EVLO) saw 1,373,871 shares changing hands with its beta currently measuring 0.98. Company’s recent per share price level of $4.9 trading at $0.89 or 22.19% at ring of the bell on the day assigns it a market valuation of $158.43 Million. That closing price of EVLO’s stock is at a discount of -100.41% from its 52-week high price of $9.82 and is indicating a premium of 38.57% from its 52-week low price of $3.01. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 148.22 Million shares which gives us an average trading volume of 81.54 Million if we extend that period to 3-months.
For Evelo Biosciences, Inc. (EVLO), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.5. Splitting up the data highlights that, out of 3 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 1 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.77 in the current quarter.
Evelo Biosciences, Inc. (NASDAQ:EVLO) trade information
Upright in the green today for gaining 22.19%, in the last five days EVLO remained trading in the green while hitting it’s week-highest on Thursday, Jun 25 when the stock touched $5.15-4 price level, adding 4.85% to its value on the day. Evelo Biosciences, Inc.’s shares saw a change of 20.69% in year-to-date performance and have moved 36.49% in past 5-day. Evelo Biosciences, Inc. (NASDAQ:EVLO) showed a performance of 14.22% in past 30-days. Number of shares sold short was 1.67 Million shares which calculate 0.02 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $7 to the stock, which implies a rise of 42.86% to its current value. Analysts have been projecting $6 as a low price target for the stock while placing it at a high target of $8. It follows that stock’s current price would jump +63.27% in reaching the projected high whereas dropping to the targeted low would mean a loss of 22.45% for stock’s current value.
Evelo Biosciences, Inc. (EVLO) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -39.7% while estimates for its earnings growth in next 5 years are of 0%
Evelo Biosciences, Inc. (NASDAQ:EVLO)’s Major holders
Insiders are in possession of 0.13% of company’s total shares while institution are holding 86.57% percent of that, with stock having share float percentage of 86.68%. Investors also watch the number of corporate investors in a company very closely, which is 72 institutions for Evelo Biosciences, Inc. that are currently holding shares of the company. Flagship Pioneering Inc. is the top institutional holder at EVLO for having 18.23 Million shares of worth $68.47 Million. And as of March 30, 2020, it was holding 56.39% of the company’s outstanding shares.
The second largest institutional holder is FMR, LLC, which was holding about 3.22 Million shares on March 30, 2020. The number of shares represents firm’s hold over 9.96% of outstanding shares, having a total worth of $12.09 Million.
On the other hand, Fidelity Growth Company Fund and Fidelity Series Growth Company Fund are the top two Mutual Funds which own company’s shares. As of February 28, 2020, the former fund manager was holding 1472187 shares of worth $7.45 Million or 4.55% of the total outstanding shares. The later fund manager was in possession of 296.14 Thousand shares on February 28, 2020, making its stake of worth around $1.5 Million in the company or a holder of 0.92% of company’s stock.